Journal of the American Society of Nephrology, Vol 5, 1895-1902, Copyright © 1995 by American Society of Nephrology

REGULAR ARTICLES

Deoxyspergualin inhibits mesangial cell proliferation and major histocompatibility complex class II expression

DJ Nikolic-Paterson, GH Tesch, HY Lan, R Foti and RC Atkins
Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.

It has previously been shown that the immunosuppressive drug deoxyspergualin can inhibit renal injury in experimental glomerulonephritis. This study examined whether deoxyspergualin can modulate the mesangial cell response to glomerular injury. Antiglomerular basement membrane glomerulonephritis was induced in primed rats. Groups of five animals were treated with deoxyspergualin (5 mg/kg per day) or saline from Day 0 until being euthanized on Day 1, 7, 14, or 21. Deoxyspergualin treatment significantly inhibited mesangial cell proliferation (proliferating cell nuclear antigen expression) over the disease course as assessed by double immunohistochemistry staining (P < 0.001 versus saline treated) and reduced glomerular major histocompatibility complex (MHC) class II expression. To demonstrate if this was a direct action of deoxyspergualin, an in vitro system was studied. The addition of deoxyspergualin caused a time- and dose-dependent inhibition of [3H]thymidine uptake by cultured rat mesangial cells. Of particular interest was the finding that deoxyspergualin inhibited the de novo cell surface expression of MHC class II antigens after interferon-gamma stimulation. However, deoxyspergualin did not prevent the cytoplasmic accumulation of MHC class II molecules, indicating that the drug interfered with a posttranslational event in MHC class II processing and/or assembly. Deoxyspergualin was not a general inhibitor of mesangial cells, and it had no effect on constitutive or lipopolysaccharide-induced transforming growth factor beta 1 expression. In conclusion, deoxyspergualin has been shown to inhibit the mesangial cell response to glomerular injury. This novel mode of action may provide an additional therapeutic benefit in the treatment of proliferative forms of glomerulonephritis.

This article has been cited by other articles:

				R. Birck, M. Newman, C. Braun, I. Neumann, K. Nemoto, B. Yard, R. Waldherr, and F. J. van der Woude 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis Nephrol. Dial. Transplant., January 1, 2006; 21(1): 58 - 63. [Abstract] [Full Text] [PDF]

				R. Birck, K. Warnatz, H. M. Lorenz, M. Choi, M. Haubitz, M. Grunke, H. H. Peter, J. R. Kalden, U. Gobel, J. M. Drexler, et al. 15-Deoxyspergualin in Patients with Refractory ANCA-Associated Systemic Vasculitis: A Six-Month Open-Label Trial to Evaluate Safety and Efficacy J. Am. Soc. Nephrol., February 1, 2003; 14(2): 440 - 447. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673